'On consolidated basis

Quarter ended December 2025 compared with Quarter ended December 2024.

Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 9.67% to Rs 1041.26 crore.  Operating profit margin has jumped from 30.75% to 35.66%, leading to 27.21% rise in operating profit to Rs 371.34 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 11.44% to 8.20%.   Purchase of finished goods cost rose from 19.28% to 22.29%.   Employee cost increased from 14.64% to 15.58%.   Other expenses fell from 20.38% to 15.82%.   

Other income fell 8.41% to Rs 32.12 crore.  PBIDT rose 23.39% to Rs 403.46 crore.  Provision for interest rose 1,222.22% to Rs 1.19 crore.  

PBDT rose 23.06% to Rs 402.27 crore.  Provision for depreciation rose 8.09% to Rs 20.32 crore.  

Profit befo...

• 

  (26-Feb-2026)

  Foseco India

  Net down 35% on higher EO Exp
• 

  (26-Feb-2026)

  KSB

  Net up 11%, sales up 8%
• 

  (26-Feb-2026)

  Sanofi India

  OP down 23.67%
• 

  (25-Feb-2026)

  Schaeffler India

  Revenue jumps 28% and profit spurts 36% in Q4CY25